Feedback Share Discussion Threads

[someuwin] 06/10/2015 13:15

There's a lot to like here - not least the very low mkt cap.

[blueball] 06/10/2015 12:45

Bought some more @3.14p.

largely because if the Ichimoku Kumo breakout last night.

[someuwin] 06/10/2015 11:21

Looks very good.

[kenwrong] 06/10/2015 10:29

The Quibim tie up and NHS alert should prove once and for all that this Feedback is no one hit wonder. Thanks Zuess, as you say these markets will all be taking the Texrad software which should then become the benchmark standard. Malcolm Stacy has written about Feedback again this morning at Shareprophets quote "It doesn't look to this old punter that the market has woken up to the fact that the technology, known as TexRAD, is so useful" unquote - Exciting times for us all!!

[lr2] 06/10/2015 10:16

Thanks Blueball.

I posted the NHS alert on here last Friday night (post #865) and nobody seemed to register the importance of it other than Britstox. Just as well Feedback got around to announcing the news today as my post had no effect on the share price. :)

[blueball] 06/10/2015 10:12

Yes well done LR2 spot on with your post 865.

[zeuss1] 06/10/2015 10:11

So we have a global prostate cancer market estimated to be worth some $50bn in 2017. Now the NHS have flagged TexRAD's potential as a tool for assessing patients with lung cancer. There are multiple potential other applications for TexRAD that will no doubt feature in Feedback's development, but for now this is a very exciting little company with a potential life saving technology that is still worth just £4.5m.

[blueball] 06/10/2015 09:58

My target is 5p here wont be long according to the news today.

[blueball] 05/10/2015 19:08

stay long.

[blueball] 05/10/2015 19:08

Ichimoku Kumo break-out.

[zeuss1] 05/10/2015 09:33

So hot on the heels of the Stone Checker jv between Feedback and UK Urology, we have another much larger marketplace application for Texrad. A new jv with Quibim called Prostate Checker Ltd hxxp://prostatechecker.co.uk sees Texrad adapted for use by clinicians in diagnosing and assessing treatment options for prostate cancer. This new announcement dwarfs the Stone Checker jv in terms of its global potential, and should see brokers covering Feedback (FDBK) re rate the stock to take in this new potential revenue stream.

[blueball] 04/10/2015 11:05

Zac Mir has a 3.5p target.

[lr2] 04/10/2015 00:56

TexRAD usage in metastatic colorectal cancer trial.

CT texture analysis as a prognostic marker in metastatic colorectal cancer patients treated with bevacizumab.

[britstox] 02/10/2015 23:47

I totally agree. For feedback to say they wouldn't be concerned on concentrating on the NHS firstly and then the NHS decide to take it up says an awful lot about its potential. There aim originally was south Korea, China, with America and Britain being later. To have the NHS say that now means a lot to the potential of the company. Hold on tight!

[lr2] 02/10/2015 22:33

I don't believe the NHS can ignore this product. It can assist in diagnosis of treatment over multiple illnesses as followers here are well aware...

"This image processing software is intended for use in patients with lung cancer undergoing radiological assessment with CT and could assist in further risk-stratification of patients with non-small cell lung cancer (NSCLC). The company claim that TexRAD could also be used to assess the prognosis of patients with colorectal, breast and oesophageal cancer."

...and it is simple to use meaning cost savings in house for NHS hospitals.

"The company claim that these benefits can be achieved at minimal cost and with minimal training of the operators such as radiographers and radiologists."

I expect world-wide pick-up of this product in a fairly short space of time.

[britstox] 02/10/2015 22:17

Exactly what we need. I'd read previously in an article that the NHS would not be taking on much because of funding so to hear they're interested in this proves again it's got some real promise. Thanks.

[lr2] 02/10/2015 21:43

Texture analysis of Radiological images (TexRAD) for lung cancer assessment.

You can download this report from the following link.



"The company anticipates CE marking by Q1 2016 and clinical use in the NHS by Q2 2017."

Commercial availability in the NHS (and presumably throughout the EEC) within 18 months.

[blueball] 30/9/2015 18:39

Late reported trade 500k @2.35p.

[britstox] 30/9/2015 17:58

Ah you've just done that!

[britstox] 30/9/2015 17:58

Thanks blueball. Thought I'd add it on as watched it. http://www.tradersown.co.uk/company/278409/Feedback-Plc

[lr2] 30/9/2015 17:51

Here's the link.